SCHEMBL24819908

SCHEMBL24819908

Cc1nc(N)ccc1Nc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 11/20 0.47
ALDH1A1 P00352 10/20 0.47
MAPT P10636 8/20 0.47
KDM4E B2RXH2 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
LMNA P02545 2/20 0.47
NOS3 P29474 1/20 0.45
NOS1 P29475 1/20 0.45
NOS2 P35228 1/20 0.45
ALOX15 P16050 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
HTT P42858 2/20 0.44
CSNK2A1 P68400 1/20 0.43
PLK3 Q9H4B4 1/20 0.43
DHFR P00374 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28797572 0.82 NR1I2 (0.49) GAAALDH1A1MAPTMEN1KMT2A
SCHEMBL7222434 0.74 NOS2 (0.54) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL27853558 0.74 KMT2A (0.50) GAAALDH1A1MAPTKDM4EMEN1
SCHEMBL18880697 0.73 CYP1A2 (0.56) GAAALDH1A1MAPTKDM4EMEN1
Hydrochloric Acid SCHEMBL7450043 0.72 NOS2 (0.52) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL19354956 0.72 NOS2 (0.52) GAAALDH1A1MAPTKDM4ELMNA
SCHEMBL30069114 0.71 MAPT (0.57) MAPTMEN1KMT2ACYP1A2CYP2D6
SCHEMBL24821505 0.71 MAPT (0.57) MAPTMEN1KMT2ACYP1A2CYP2D6
Diphenylamine SCHEMBL23722810 0.71 HSD17B10 (0.57) GAAALDH1A1MAPTKDM4EMEN1
SCHEMBL13821828 0.71 TDP1 (0.50) GAAALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346562-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR IREGENE THERAPEUTICS LTD (CN) 2025-11-13 US disclosed
CN-115572285-B OCT4 high-selectivity activator 武汉睿健医药科技有限公司 2024-10-29 CN disclosed
EP-4361131-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR Iregene Therapeutics Ltd (CN) 2024-05-01 EP disclosed
CN-115572256-A OCT4 high selectivity activator 武汉睿健医药科技有限公司 2023-01-06 CN disclosed
CN-115572285-A OCT4 high selectivity activator 武汉睿健医药科技有限公司 2023-01-06 CN disclosed
WO-2022266794-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR 武汉睿健医药科技有限公司 2022-12-29 WO disclosed
WO-2022266794-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR 武汉睿健医药科技有限公司 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346562-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR POU2F1, POU5F1, POU2F2 GAA 2403/4885ALDH1A1 40/4885MAPT 3864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.